MTHFR C677T polymorphism contributes to colorectal cancer susceptibility: evidence from 61 case-control studies. 2012

Xuewen Sheng, and Yanxi Zhang, and Erjiang Zhao, and Su Lu, and Xiaoli Zheng, and Hong Ge, and Weiquan Lu
Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou 450001, China.

Methylenetetrahydrofolate reductase (MTHFR) is believed to be involved in folate metabolism which plays a critical role in carcinogenesis. To date, many case-control studies have investigated the association between MTHFR C677T polymorphism and colorectal cancer risk. However, the results were inconsistent. In order to derive a more precise estimation of the association, we conducted this meta-analysis. This meta-analysis recruited 61 published studies which were selected by a search of PubMed up to 31st September 2011, including 16,111 colorectal cancer cases and 23,192 controls. We used crude odds ratios (ORs) with 95 % confidence intervals (CIs) to assess the association between MTHFR C677T polymorphism and colorectal cancer susceptibility. Our results showed that MTHFR C667T polymorphism contributed to the decreased colorectal cancer risk in overall population (for TT vs. CC: OR = 0.89, 95 % CI = 0.82-0.97; for TT vs. CT/CC: OR = 0.88, 95 % CI = 0.83-0.92). In subgroup analysis by ethnicity, the results also indicated a correlation between the T allele of MTHFR C667T and the colorectal cancer risk in Asian population (for TT vs. CC: OR = 0.82, 95 % CI = 0.69-0.97; for TT vs. CT/CC: OR = 0.81, 95 % CI = 0.74-0.90). Additionally, the correlation was also observed in male subgroup in sub-analysis by gender (for TT vs. CC: OR = 0.82, 95 % CI = 0.71-0.93; for TT vs. CT/CC: OR = 0.81, 95 % CI = 0.71-0.92). In summary, our meta-analysis strongly indicated the MTHFR C667T polymorphism was associated with a reduced risk of CRC.

UI MeSH Term Description Entries
D008297 Male Males
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012306 Risk The probability that an event will occur. It encompasses a variety of measures of the probability of a generally unfavorable outcome. Relative Risk,Relative Risks,Risk, Relative,Risks,Risks, Relative
D012737 Sex Factors Maleness or femaleness as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or effect of a circumstance. It is used with human or animal concepts but should be differentiated from SEX CHARACTERISTICS, anatomical or physiological manifestations of sex, and from SEX DISTRIBUTION, the number of males and females in given circumstances. Factor, Sex,Factors, Sex,Sex Factor
D015179 Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI. Colorectal Cancer,Colorectal Carcinoma,Colorectal Tumors,Neoplasms, Colorectal,Cancer, Colorectal,Cancers, Colorectal,Carcinoma, Colorectal,Carcinomas, Colorectal,Colorectal Cancers,Colorectal Carcinomas,Colorectal Neoplasm,Colorectal Tumor,Neoplasm, Colorectal,Tumor, Colorectal,Tumors, Colorectal
D016017 Odds Ratio The ratio of two odds. The exposure-odds ratio for case control data is the ratio of the odds in favor of exposure among cases to the odds in favor of exposure among noncases. The disease-odds ratio for a cohort or cross section is the ratio of the odds in favor of disease among the exposed to the odds in favor of disease among the unexposed. The prevalence-odds ratio refers to an odds ratio derived cross-sectionally from studies of prevalent cases. Cross-Product Ratio,Risk Ratio,Relative Odds,Cross Product Ratio,Cross-Product Ratios,Odds Ratios,Odds, Relative,Ratio, Cross-Product,Ratio, Risk,Ratios, Cross-Product,Ratios, Risk,Risk Ratios
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D017594 Publication Bias The influence of study results on the chances of publication and the tendency of investigators, reviewers, and editors to submit or accept manuscripts for publication based on the direction or strength of the study findings. Publication bias has an impact on the interpretation of clinical trials and meta-analyses. Bias can be minimized by insistence by editors on high-quality research, thorough literature reviews, acknowledgement of conflicts of interest, modification of peer review practices, etc. Bias, Publication
D042965 Methylenetetrahydrofolate Reductase (NADPH2) A flavoprotein amine oxidoreductase that catalyzes the reversible conversion of 5-methyltetrahydrofolate to 5,10-methylenetetrahydrofolate. This enzyme was formerly classified as EC 1.1.1.171. Methylene-THF Reductase (NADPH),5,10-Methylenetetrahydrofolate Reductase (NADPH),Methylene Tetrahydrofolate Reductase,Methylenetetrahydrofolate Reductase,Methylenetetrahydrofolate Reductase (NADPH),Tetrahydrofolate Reductase, Methylene

Related Publications

Xuewen Sheng, and Yanxi Zhang, and Erjiang Zhao, and Su Lu, and Xiaoli Zheng, and Hong Ge, and Weiquan Lu
January 2013, PloS one,
Xuewen Sheng, and Yanxi Zhang, and Erjiang Zhao, and Su Lu, and Xiaoli Zheng, and Hong Ge, and Weiquan Lu
January 2015, Neuroscience letters,
Xuewen Sheng, and Yanxi Zhang, and Erjiang Zhao, and Su Lu, and Xiaoli Zheng, and Hong Ge, and Weiquan Lu
November 2015, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Xuewen Sheng, and Yanxi Zhang, and Erjiang Zhao, and Su Lu, and Xiaoli Zheng, and Hong Ge, and Weiquan Lu
May 2012, Mutagenesis,
Xuewen Sheng, and Yanxi Zhang, and Erjiang Zhao, and Su Lu, and Xiaoli Zheng, and Hong Ge, and Weiquan Lu
January 2012, PloS one,
Xuewen Sheng, and Yanxi Zhang, and Erjiang Zhao, and Su Lu, and Xiaoli Zheng, and Hong Ge, and Weiquan Lu
July 2014, Molecular biology reports,
Xuewen Sheng, and Yanxi Zhang, and Erjiang Zhao, and Su Lu, and Xiaoli Zheng, and Hong Ge, and Weiquan Lu
January 2012, PloS one,
Xuewen Sheng, and Yanxi Zhang, and Erjiang Zhao, and Su Lu, and Xiaoli Zheng, and Hong Ge, and Weiquan Lu
March 2011, PloS one,
Xuewen Sheng, and Yanxi Zhang, and Erjiang Zhao, and Su Lu, and Xiaoli Zheng, and Hong Ge, and Weiquan Lu
March 2014, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Xuewen Sheng, and Yanxi Zhang, and Erjiang Zhao, and Su Lu, and Xiaoli Zheng, and Hong Ge, and Weiquan Lu
February 2015, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Copied contents to your clipboard!